​

BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BBIO Stock Forecast

BridgeBio Pharma (BBIO) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $72.25, with a high of $80.00 and a low of $68.00. This represents a 13.67% increase from the last price of $63.56.

$20 $32 $44 $56 $68 $80 High: $80 Avg: $72.25 Low: $68 Last Closed Price: $63.56

BBIO Stock Rating

BridgeBio Pharma stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (95.65%), 1 Hold (4.35%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 1 22 Strong Sell Sell Hold Buy Strong Buy

BBIO Price Target Upside V Benchmarks

TypeNameUpside
StockBridgeBio Pharma13.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts345
Avg Price Target$72.33$71.75$71.80
Last Closing Price$63.56$63.56$63.56
Upside/Downside13.80%12.89%12.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 254141--19
Sep, 254151-121
Aug, 255152--22
Jul, 256113--20
Jun, 256103--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025H.C. Wainwright$80.00$63.3326.32%25.87%
Oct 27, 2025Raymond James$69.00$63.219.16%8.56%
Oct 27, 2025Mani ForooharLeerink Partners$68.00$63.616.90%6.99%
Aug 29, 2025Raghuram SelvarajuH.C. Wainwright$70.00$51.5135.90%10.13%
Apr 30, 2025Eliana MerleUBS$72.00$38.3687.70%13.28%
Oct 24, 2024David LebowitzCitigroup$45.00$24.1786.18%-29.20%
Oct 17, 2024Mani ForooharLeerink Partners$46.00$26.3474.64%-27.63%
Sep 11, 2024Biren AminPiper Sandler$46.00$28.7859.83%-27.63%
Sep 03, 2024Salim SyedMizuho Securities$53.00$29.9277.14%-16.61%
Jun 24, 2024Danielle BrillRaymond James$46.00$22.65103.09%-27.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025H.C. WainwrightBuyBuyhold
Oct 27, 2025Raymond JamesOutperformOutperformhold
Oct 27, 2025Leerink PartnersOutperformOutperformhold
Oct 27, 2025Evercore ISIOutperformOutperformhold
Sep 12, 2025UBSBuyBuyhold
Aug 29, 2025H.C. WainwrightBuyBuyhold
Jul 14, 2025JefferiesBuyinitialise
Jun 17, 2025Wolfe ResearchOutperforminitialise
Apr 30, 2025UBSBuyBuyhold
Oct 24, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.10$-4.43$-3.35$-3.95$-2.88----
Avg Forecast$-3.52$-3.70$-3.13$-3.76$-2.52$-3.55$-2.51$-0.57$1.91
High Forecast$-1.46$-1.53$-1.18$-3.60$-2.32$-2.63$-0.86$0.68$4.02
Low Forecast$-8.94$-9.39$-7.28$-3.97$-2.70$-4.27$-3.28$-0.95$0.30
Surprise %16.48%19.73%7.03%5.05%14.29%----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.25M$69.72M$77.65M$9.30M$221.90M----
Avg Forecast$22.52M$78.26M$82.75M$12.29M$219.05M$176.98M$437.33M$967.67M$1.67B
High Forecast$49.15M$170.79M$167.23M$16.09M$230.15M$313.43M$442.24M$1.01B$3.08B
Low Forecast$12.38M$43.03M$43.07M$7.40M$214.98M$64.02M$432.43M$928.41M$588.98M
Surprise %-63.37%-10.91%-6.16%-24.31%1.30%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-483.93M$-639.30M$-493.96M$-643.20M$-535.76M----
Avg Forecast$-362.63M$-450.77M$-570.76M$-643.20M$-438.86M$-561.83M$-336.28M$-21.66M$311.59M
High Forecast$-290.11M$-360.62M$-456.61M$-514.56M$-376.93M$-428.14M$-139.25M$110.71M$654.37M
Low Forecast$-435.16M$-540.92M$-684.91M$-771.84M$-439.49M$-695.53M$-533.31M$-154.03M$49.48M
Surprise %33.45%41.82%-13.45%-22.08%----

BBIO Forecast FAQ

Is BridgeBio Pharma stock a buy?

BridgeBio Pharma stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BridgeBio Pharma is a favorable investment for most analysts.

What is BridgeBio Pharma's price target?

BridgeBio Pharma's price target, set by 23 Wall Street analysts, averages $72.25 over the next 12 months. The price target range spans from $68 at the low end to $80 at the high end, suggesting a potential 13.67% change from the previous closing price of $63.56.

How does BridgeBio Pharma stock forecast compare to its benchmarks?

BridgeBio Pharma's stock forecast shows a 13.67% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BridgeBio Pharma over the past three months?

  • October 2025: 21.05% Strong Buy, 73.68% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 19.05% Strong Buy, 71.43% Buy, 4.76% Hold, 0% Sell, 4.76% Strong Sell.
  • August 2025: 22.73% Strong Buy, 68.18% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is BridgeBio Pharma’s EPS forecast?

BridgeBio Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.55, marking a 23.26% increase from the reported $-2.88 in 2024. Estimates for the following years are $-2.51 in 2026, $-0.57 in 2027, and $1.91 in 2028.

What is BridgeBio Pharma’s revenue forecast?

BridgeBio Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $176.98M, reflecting a -20.24% decrease from the reported $221.9M in 2024. The forecast for 2026 is $437.33M, followed by $967.67M for 2027, and $1.67B for 2028.

What is BridgeBio Pharma’s net income forecast?

BridgeBio Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-562M, representing an 4.87% increase from the reported $-536M in 2024. Projections indicate $-336M in 2026, $-21.661M in 2027, and $311.59M in 2028.